pipobroman has been researched along with Acute Disease in 7 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 6.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980." | 6.18 | Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". ( Dresch, C; Echard, M; Goguel, A; Grange, MJ; Lejeune, F; Najean, Y; Rain, JD, 1996) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 2.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernasconi, P | 1 |
| Boni, M | 1 |
| Cavigliano, PM | 1 |
| Calatroni, S | 1 |
| Brusamolino, E | 1 |
| Passamonti, F | 2 |
| Volpe, G | 1 |
| Pistorio, A | 1 |
| Giardini, I | 1 |
| Rocca, B | 1 |
| Caresana, M | 1 |
| Lazzarino, M | 2 |
| Bernasconi, C | 1 |
| Paitel, JF | 1 |
| Trechot, P | 1 |
| Stockemer, V | 1 |
| Dorvaux, V | 1 |
| Lederlin, P | 1 |
| Boivin, P | 1 |
| Najean, Y | 1 |
| Rain, JD | 1 |
| Dresch, C | 1 |
| Goguel, A | 1 |
| Lejeune, F | 1 |
| Echard, M | 1 |
| Grange, MJ | 1 |
| Sánchez Fayos, J | 1 |
| Román Barbero, A | 1 |
| Nevado Reviriego, I | 1 |
| Tefferi, A | 1 |
3 reviews available for pipobroman and Acute Disease
| Article | Year |
|---|---|
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Topics: Abortion, Spontaneous; Acute Disease; Alkylating Agents; Female; Humans; Leukemia, Myeloid; Middle A | 2003 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1997 |
2 trials available for pipobroman and Acute Disease
| Article | Year |
|---|---|
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Topics: Acute Disease; Bloodletting; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia; Phosphorus Ra | 1993 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
3 other studies available for pipobroman and Acute Disease
| Article | Year |
|---|---|
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Female; Humans; H | 2002 |
[Acute liver disease during treatment with pipobroman and allopurinol].
Topics: Acute Disease; Allopurinol; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Pipob | 1995 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |